Bonterra Energy Announces Third Quarter 2025 Financial Results and Operations Update

The Company Achieves a 7% Increase in YTD Production, Reduces Net Debt, and Maintains Production and Capital Expenditure ...

CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)

PRESS RELEASE AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutationsFirst-in-human ...